bioRxiv preprint doi: https://doi.org/10.1101/214155; this version posted November 6, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Combined Androgen Administration and HDAC Inhibition in Experimental Cancer Cachexia Yu-Chou Tseng1, Sophia G. Liva2, Anees M. Dauki2, Sally E. Henderson1, Yi-Chiu Kuo1, Jason A. Benedict3, Samuel K. Kulp1, Tanois Bekaii-Saab5, Ching-Shih Chen1 and Christopher C. Coss2,4 1Divison of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 2Divison of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 3Center for Biostatistics, OSU Comprehensive Cancer Center, The Ohio State University, Columbus, OH 4Pharmacoanalytical Shared Resource, OSU Comprehensive Cancer Center, The Ohio State University, Columbus, OH 5Mayo Clinic Cancer Center, Phoenix, AZ Corresponding Author(s): Ching-Shih Chen PhD Mailing Address: The Ohio State University College of Pharmacy, 500 W.12th Ave, Columbus OH, 43210 Phone: 614-688-4008 Fax: (614) 292-7766 E-mail:
[email protected] Christopher C. Coss PhD Mailing Address: The Ohio State University College of Pharmacy, 500 W.12th Ave, Columbus OH, 43210 Phone:614-688-1309 Fax: (614) 292-7766 E-mail:
[email protected] Target Journal: Journal of Cachexia, Sarcopenia and Muscle IF 9.6 Abstract word count (400 max): 252 Manuscript word count: 8,500 Tables/Figures: 6 Figures, 1 Table; References: bioRxiv preprint doi: https://doi.org/10.1101/214155; this version posted November 6, 2017.